Latest Breaking News On - Breast cancer annual congress - Page 1 : vimarsana.com

Dato-DXd May Be Better Tolerated Than Chemo in HR+/HER2– Breast Cancer

No Improvement in OS With Atezolizumab in Relapsing TNBC

Early relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug.

Arvinas, Pfizer Update Phase 1b Trial Data for Vepdegestrant, Palbociclib

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Cancer screening: Early detection saves Canada's healthcare system millions, uOttawa says

Researchers at the University of Ottawa (uOttawa) say while recent research shows breast cancer cases are on the rise among younger Canadians (Link), early diagnosis not only saves lives, but also saves the country's healthcare system nearly $500 million.

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

T-DXd Maintains Survival Advantage Over Physician's Choice of Therapy in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Olema Oncology Announces Promising New Data for

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer